All Stories

  1. Effect of Specialized Psychiatric Assessment and Precision Diagnosis on Pharmacotherapy in Adults with Intellectual Disability
  2. Eating Disorders and Autistic Traits Camouflaging: Insights from the EAT Study
  3. Effect of Specialized Psychiatric Assessment and Precision Diagnosis On Pharmacotherapy in Adults with Intellectual Disability
  4. Effects of palmitoylethanolamide in clinical high-risk for psychosis: A nonrandomized open-label trial
  5. Mental health prevention: moving forward with the evidence
  6. Revisiting Franco Basaglia’s legacy: theoretical and clinical implications for modern psychiatry: commentary, Colizzi
  7. Neurodevelopmental burden in young adults undergoing opioid substitution therapy: The role of inattentive and hyperactive/impulsive symptoms
  8. Examining psychological protective mechanisms as moderators of the association between autistic traits and psychosis expression in a general population twin sample
  9. Maternal vulnerability to insomnia: Relationship with poor newborn sleep and peripartum psychopathology
  10. Ten priorities that are shaping the future of mental health prevention
  11. Trends in suicide attempts and deaths in Northeast Italy (2014 to 2023): A rising burden among young women
  12. Defining the Scientist: A Consensus-Based Approach
  13. Psychological interventions tailored to the needs of individuals with hearing and visual impairments: What do we know and what should we do? A commentary on “A systematic review and meta-analysis of psychological interventions for persons with hearing ...
  14. Post-COVID-19 Syndrome as Described by Patients: A Qualitative Study
  15. Editorial: Case reports in autism: 2023
  16. Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations
  17. In Web We Trust: The Promised Cannabidiol Effects on Obesity as a Matter of Language and Marketing on Webpages
  18. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network a...
  19. The Moderating Role of Genetic and Environmental Risk Factors for Schizophrenia on the Relationship between Autistic Traits and Psychosis Expression in the General Population
  20. The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis
  21. Clinical heterogeneity of feeding and eating disorders: using personality psychopathology to differentiate “simplex” and “complex” phenotypes
  22. Is a No-Restraint Policy Associated with Increased Aggression Towards Healthcare Professionals Among Inpatient Psychiatric Units? A 16-Year Retrospective Observational Study Conducted in Italy
  23. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study
  24. Challenges in addressing youth mental health
  25. Collaborative Outcomes Study on Health and Functioning During Infection Times (COH-FIT): Global and Risk-Group Stratified Course of Well-Being and Mental Health During the COVID-19 Pandemic in Adolescents
  26. Occupational Stress Among Italian Postgraduate Medical Trainees: A Pilot Study for the Validation of the SCOPE Questionnaire
  27. Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases
  28. Lessons Learnt From Running a Transition‐Age Youth Mental Health Outpatient Clinic in Italy: The PRecocity of Intervention in Adolescent Medicine (PRIMA) Experience
  29. Cannabidiol (CBD) Listed as a Drug of Abuse by the Italian Health Ministry: Expert Opinion
  30. CaReL Guideline: A Consensus-Based Guideline on Case Reports and Literature Review (CaReL)
  31. The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults
  32. Prevalence and risk factors for depression in factitious disorder: a systematic review
  33. Tic-Related Obsessive–Compulsive and Eating Disorders in Dandy–Walker Variant: A Case Report and Systematic Reappraisal of Psychiatric Profiles
  34. Prenatal insomnia disorder may predict concurrent and postpartum psychopathology: A longitudinal study
  35. COVID-19-induced neuropsychiatric symptoms can persist long after acute infection: a 2-year prospective study of biobehavioral risk factors and psychometric outcomes
  36. Editorial: Case reports in autism
  37. Pediatric emergency department mental health assessments in the 2 years following the COVID-19 outbreak reveal higher vulnerability for eating disorder and suicide risk
  38. Impact of COVID-19 on behavior in autism spectrum disorder
  39. Risk of psychosis in autism spectrum disorder individuals exposed to psychosocial stressors: A 9‐year chart review study
  40. Lessons learnt while designing and conducting a longitudinal study from the first Italian COVID-19 pandemic wave up to 3 years
  41. Psychological factors associated with vaccination hesitancy: an observational study of patients hospitalized for COVID-19 in a later phase of the pandemic in Italy
  42. Editorial: Advances in understanding the pathogenetic mechanisms of neurodevelopmental disorders and neurodegenerative disease — The environment as a putative risk factor
  43. Biobehavioral Interactions between Endocannabinoid and Hypothalamic-pituitary-adrenal Systems in Psychosis: A Systematic Review
  44. Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
  45. COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection
  46. Editorial: Developmental trajectories in mental health between adolescence and adulthood
  47. Confirmation of increased and more severe adolescent mental health-related in-patient admissions in the COVID-19 pandemic aftermath: A 2-year follow-up study
  48. Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK
  49. Mentalization in young patients undergoing opioid agonist treatment: Implications for clinical management
  50. Changes in Revolving-Door Mental Health Hospitalizations during the COVID-19 Pandemic: A 5-Year Chart Review Study
  51. Where Do Neurodevelopmental Disorders Go? Casting the Eye Away from Childhood towards Adulthood
  52. Association between stressful life events and psychosis relapse: a 2‐year prospective study in first‐episode psychosis
  53. Using Metaphors to Understand Suffering in COVID-19 Survivors: A Two Time-Point Observational Follow-Up Study
  54. Prevalence and Risk Factors for Absconding from an Open-Door, No-Restraint Inpatient Psychiatric Unit: A Single-Center Study in Italy
  55. Uncovering Mental Health Insights: Exploring Cannabis and Psychosis Link in the UK
  56. Editorial: Methods and applications in addiction psychiatry research: 2021
  57. Development and Reliability of a Questionnaire Assessing Stress, Coping, and Empathy (SCOPE) in Occupational Settings: Preliminary Evidence from Veterinarians
  58. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  59. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence
  60. Feigning Capgras Syndrome and Developmental Prosopagnosia: a rare case of Pediatric Factitious Disorder?
  61. Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis
  62. Mental health symptoms one year after acute COVID-19 infection: prevalence and risk factors
  63. The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System
  64. Sociodemographic and clinical changes in pediatric in-patient admissions for mental health emergencies during the COVID-19 pandemic: March 2020 to June 2021
  65. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)
  66. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  67. Gender-Oriented Mental Health Prevention: A Reappraisal
  68. Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence
  69. Neurodevelopmental Disorders and Psychosocial Issues Later in Life
  70. Prevention in Mental Health
  71. Further evidence on the interplay between benzodiazepine and Z-drug abuse and emotion dysregulation
  72. Additional Evidence for Neuropsychiatric Manifestations in Mosaic Trisomy 20: A Case Report and Brief Review
  73. Meet the Editorial Board Member
  74. Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry
  75. 21.5 Repercussions of the First and Second COVID-19 Waves in the Italian Pediatric Population: An Inpatient Psychiatric Emergency Study
  76. Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases
  77. Epigenetic Mediation of AKT1 rs1130233’s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing
  78. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence
  79. Effectiveness of Equine-Assisted Activities and Therapies for Improving Adaptive Behavior and Motor Function in Autism Spectrum Disorder
  80. Postural Control in Childhood: Investigating the Neurodevelopmental Gradient Hypothesis
  81. The Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome: Preliminary Evidence from a Case Series
  82. Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior
  83. Adolescent Lifestyle Behaviors, Coping Strategies and Subjective Wellbeing during the COVID-19 Pandemic: An Online Student Survey
  84. Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol
  85. 4.4 IS ALTERED SENSORIMOTOR INTEGRATION A CORE FEATURE OF TOURETTE'S DISORDER? A CASE-CONTROL STUDY
  86. 51.18 THE COVID-19 OUTBREAK IMPACT ON WELL-BEING AMONG PEOPLE WITH AUTISM SPECTRUM DISORDER IN ITALY: AN N = 527 WEB-BASED SURVEY
  87. Investigating Gait, Movement, and Coordination in Children with Neurodevelopmental Disorders: Is There a Role for Motor Abnormalities in Atypical Neurodevelopment?
  88. Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
  89. Psychosocial and Behavioral Impact of COVID-19 in Autism Spectrum Disorder: An Online Parent Survey
  90. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
  91. Medically unexplained symptoms in the times of COVID-19 pandemic: A case-report
  92. Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis
  93. Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?
  94. Cannabis and Cognition: Connecting the Dots towards the Understanding of the Relationship
  95. Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review
  96. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study
  97. The 2019 Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: A summary of topics and trends
  98. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
  99. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
  100. Is there sufficient evidence that cannabis use is a risk factor for psychosis?
  101. Stigma as the main obstacle in health care and human rights among people with mental disorders. A rights-based ethics approach
  102. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids
  103. Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study
  104. Differential gene expression analysis in blood of first episode psychosis patients
  105. Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans
  106. O3.4. DOES CANNABIS INDUCE PSYCHOSIS BY ALTERING GLUTAMATE SIGNALING IN THE STRIATUM?
  107. Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis
  108. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
  109. The Relationship Between Dissociative Experiences and Cannabis Use: a Systematic Review
  110. Correction to: The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
  111. Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study
  112. Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort
  113. Cannabis use and the development of tolerance: a systematic review of human evidence
  114. The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
  115. Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.
  116. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure
  117. S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
  118. F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY
  119. S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE
  120. Cannabis and psychosis: what do we know and what should we do?
  121. Do Cannabis Users Develop Tolerance for the Psychoactive Effects of Delta-9-tetrahydrocannabinol? an fMRI Study
  122. Neurocognitive effects of cannabis: Lessons learned from human experimental studies
  123. Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains
  124. Hyperprolactinaemia in first episode psychosis - A longitudinal assessment
  125. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
  126. Cannabis users are less sensitive to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration
  127. A Prediction Modelling and Pattern Detection Approach for the First-Episode Psychosis Associated to Cannabis Use
  128. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study
  129. The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review
  130. Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use
  131. To treat or not to treat: puberty suppression in childhood-onset gender dysphoria
  132. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence
  133. Substance use, medication adherence and outcome one year following a first episode of psychosis
  134. Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case–control study
  135. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2year follow-up study
  136. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis
  137. Dissociative symptoms in individuals with gender dysphoria: Is the elevated prevalence real?
  138. Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria
  139. Functional Genetic Variation of the Cannabinoid Receptor 1 and Cannabis Use Interact on Prefrontal Connectivity and Related Working Memory Behavior
  140. Poster #M195 THE INTERACTION BETWEEN CNR1 GENETIC VARIATION AND CANNABIS EXPOSURE PREDICTS PREFRONTAL FUNCTIONAL CONNECTIVITY AND BEHAVIOR DURING WORKING MEMORY
  141. Attachment Styles in Transsexual Patients and Clinical and Nonclinical Control Groups: A Response
  142. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: Results from a longitudinal study
  143. Hormonal Treatment Reduces Psychobiological Distress in Gender Identity Disorder, Independently of the Attachment Style
  144. Poster #103 INTERACTION BETWEEN COMT GENOTYPE, CANNABIS USE, AND BFQ MEASURES OF SOCIABILITY
  145. Poster #35 STUDYING EPISODIC MEMORY CEREBRAL NETWORK: A NOVEL EVENT-RELATED TASK FOR FMRI
  146. COGNITIVE DEFICITS AS INTERMEDIATE PHENOTYPE IN SCHIZOPHRENIA